Photo: Courtesy-
Metropolis Report-
Number of diabetic patients is increasing at an alarming rate in the country. Experts have advised to be more aware of diabetes prevention through healthy eating habits and regular exercise.
Addressing a diabetes screening camp at the Directorate General of Drug Administration (DGDA) on Tuesday, speakers emphasizedon controlled lifestyle as well as diabetes testing on a large scale.
DGDA and Denmark-based global leader in diabetes care Novo Nordisk organized a diabetes screening camp on the occasion ofDiabetes Awareness Day on 28 February 2023 at the premise of DGDA, at capital’s Mohakhali.
Director General Major General Mohammad Yousuf inaugurated the day long diabetes screening program.Along with him DGDA higher officials Md. Salahuddin,Md. Ashraf Hossain, Md. Ayub Hossain, Mohammad Mozammel Hossain, Dr. Md. Akter Hossain and Md. Aziullawas also at the event.
Director General of Drug Administration, Major General Mohammad Yousuf, emphasized on his speech that according to International Diabetes Federation, Bangladesh has 13 million diabetic patients which will rise to almost 20 million by 2045. Beyond this, the most alarming is that majority of the diabetic population is unaware that they have diabetes.
He also added Bangladesh Government is prioritizing and highly committed in management of diabetes. He mentioned that Hon’ble Prime Minister Sheikh Hasina was felicitated as ‘Global Ambassador for Diabetes’ at the World Diabetes Congress 2022 in Lisbon, Portugal organised by International Diabetes Federation. He also thanked the effort demonstrated by local and foreign pharmaceutical companies to ensure the latest and innovative molecules for treatment of diabetes in Bangladesh.
In reference to this occasion Rajarshi Dey Sarker, Vice President & General Manager of Novo NordiskBangladesh highlightedthat 2023 is a special year for Novo Nordisk as we are celebrating 100thanniversary of this global organization, a legacy and commitment in serving patients suffering with diabetes and other chronic diseases. For the diabetic population of Bangladesh, product of Novo Nordisk is available for last 66 years and to further strengthen the commitment an Insulin Penfill® manufacturing facility has also been established.Mezba Ul Gaffar, Director Customer Engagement, Hasan Md Moinul Islam, Director CMRQ, Shafiqul Islam, Public Affairs & Communication Manager and Uddipon Aziz, Manager PV & RA from Novo Nordisk were present at the event.
